Nanoblade technology: high efficiency delivery of crisprs components in primary cells by virus like particles.

The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Keywords: CRISPR, Cas9, Virology, Gene editing, Gene therapy
Patent Application number: EP 15 306678.2 : METHODS AND PRODUCTS FOR GENETIC ENGINEERING
Efficient genome editing in primary cells and in vivo using viral-derived 'Nanoblades' loaded with Cas9/sgRNA ribonucleoproteins

You might also be interested in


Inserm Transfert

Research tool licensing team